OTC · AMPE
Ampio Pharmaceuticals, Inc.
$0.18$0.00 (0.0%)
Ampio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.55% below the high.
Loading market information…
OTC · IRBS · USD
Stock price
Quote as of Jul 15, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
IR Biosciences Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
IR BioSciences Holdings, Inc. is a U.S.-based, early-stage biotechnology firm. Through its subsidiary, ImmuneRegen BioSciences, Inc., it concentrates on researching and developing therapies for significant health challenges, including pulmonary fibrosis, influenza infections, and neutropenia caused by radiation. The company is also actively developing Homspera and its derivatives, Radilex and Viprovex. These compounds are designed to stimulate human stem cells, enhance immune system responses, offer anti-infective properties, serve as vaccine adjuvants, and promote wound healing. Founded in 1999, IR BioSciences Holdings, Inc. maintains its headquarters in Scottsdale, Arizona.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.18$0.00 (0.0%)
Ampio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.55% below the high.
$0.00$0.00 (0.0%)
GlobeStar Therapeutics Corporation: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Hard to Treat Diseases Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
Panbela Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.56% below the high.
$0.00$0.00 (0.0%)
GB Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.98% below the high.
$0.00+$0.00 (+500.0%)
Scorpius Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
$0.00$0.00 (0.0%)
Ehouse Global, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Bioasis Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
